Tweets
POS1035 FVC & risk of lung transplant & mortality in #RAILD
50% pts had FVC % predicted decline in ~6.5yrs
2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression
#EULAR2024 @RheumNow
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 7 months ago
#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
#EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
#EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction & regurgitation) was more common in Triple Ab+ vs Non-Triple Ab. We should monitor and consider an echocardiogram for this group of patient @RheumNow https://t.co/VxFUSpjaG1
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 7 months ago
#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow
https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
📄 You can now read my article on #CardiovascularDisease, #Stroke & #Mortality @RheumNow!
🌟 Featuring 2 cohort studies from @MayoClinic, presented at #EULAR2024
🔗 https://t.co/b639vE5hSA
@MyasoedovaElena
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 7 months ago
#EULAR2024 OP0193 Watch out, blinatumomab will BiTE! Bi-specific T-cell engagers (BiTEs), kill Bcells by engaging Tcells. In 6 refractory #RA patients (failed 3 x ts/bDMARDs), deep blood & tissue depletion were met, good response. Brief raised temp but no cytokine storm @RheumNow https://t.co/OmxSbTXfZq
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
Fascinating - @ndb_org installed an app to measure smartphone usage, and texting less and moving less were associated with more flares.
The pseudo-wearable in our pockets??
#EULAR2024 POS0678 @RheumNow https://t.co/ZA0hd3Q10d
David Liew @drdavidliew ( View Tweet )
1 year 7 months ago
